Research programme: inflammation therapy - Evotec AG/Seikagaku
Latest Information Update: 06 Jan 2010
At a glance
- Originator Evotec AG; Seikagaku Corporation
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 26 Feb 2008 Preclinical development is ongoing
- 13 Aug 2004 Preclinical trials in Inflammation in Europe (unspecified route)